ArticleFrontiers in oncology2023
Bevacizumab in recurrent WHO grades II-III glioma.
Soufyan Annakib et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this paperpooled itcites it
ArticleFrontiers in oncology2023
Soufyan Annakib et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.